 |
| 8:15 AM – 9:00 AM |
Breakfast and Registration |
|
| Welcome and Introduction |
|
| 9:00 AM – 9:25 AM |
Anthony J. Sinskey
Professor of Biology; Faculty Director, Center for Biomedical Innovation, MIT
view bio |
|
| Keynote Presentations |
|
| |
Morning Chair: Stacy L. Springs, MIT CBI
view bio |
|
| 9:25 AM – 10:15 AM |
Engineering Intelligent Immunity: The Development and Future of CAR T Cell Therapies
Bruce Levine
Barbara and Edward Netter Professor in Cancer Gene Therapy, Founding Director of the Clinical Cell and Vaccine Production Facility, Department of Pathology and Laboratory Medicine and the Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania
view bio | view abstract |
|
| 10:15 AM – 10:45 AM |
FDA’s Efforts to Advance the Development of Advanced Therapy Medicinal Products
Peter Marks
Director, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration
view bio | view abstract |
|
| 10:45 AM - 11:10 AM |
Refreshment Break |
|
| Session 1: Lessons Learned and New Products |
|
| 11:10 AM – 11:35 AM |
Evolving the Manufacture of Cell-Based Therapies: Lessons Learned and Future Concepts
Rodney Rietze
Director, Strategic Development and Innovation, Novartis Pharmaceuticals
view bio | view abstract |
|
| A Panel Discussion on the Future of Innovation in Cell and Gene Therapies |
|
| 11:35 AM – 12:15 PM |
Moderated by:
J. Fraser Wright
Chief Technology Officer, Gene Therapies, Axovant Sciences
view bio
Panelists:
Bruce Levine
Barbara and Edward Netter Professor in Cancer Gene Therapy, Founding Director of the Clinical Cell and Vaccine Production Facility, Department of Pathology and Laboratory Medicine and the Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania
view bio
Peter Marks
Director, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration
view bio
Rodney Rietze
Director, Strategic Development and Innovation, Novartis Pharmaceuticals
view bio |
|
| 12:15 PM – 1:15 PM |
Lunch: Posters Available for Viewing |
|
| Session 1: Lessons Learned and New Products (continued) |
|
| |
Afternoon Chair: Paul W. Barone, MIT CBI
view bio |
|
| 1:15 PM – 1:40 PM |
Universal Gene-Edited CAR T-Cell Immunotherapy: A Future-Defining Shift in Availability and Cost Effectiveness
David Sourdive
Executive Vice President, Technical Operations, Cellectis
view bio | view abstract |
|
| 1:40 PM – 2:05 PM |
AAV Gene Therapy Analytics: Measurement, Understanding and Control of Product and Process Related Impurities
Mimi Roy
Executive Director, Analytical Chemistry, BioMarin
view bio | view abstract
|
|
| 2:05 PM – 2:30 PM |
Advancing Genetic Circuit Technologies for Next Generation Cell and Gene Therapies
Philip Lee
Co-Founder and Chief Operating Officer, Senti Biosciences
view bio | view abstract
|
|
| 2:30 PM – 2:55 PM |
Discussion on the Use of Non-Viral Cell Gene Modification for the Generation of CAR-Ts
Martin Giedlin
Vice President, Technical Operations, Poseida Therapeutics
view bio | view abstract
|
|
| 2:55 PM – 3:20 PM |
λ-Integrase-Mediated Genome Insertion Tool–A Novel and Unique Platform for Genome Engineering
Harshyaa Makhija
Research Fellow, Nanyang Technological University, Singapore-MIT Alliance for Research and Technology
view bio | view abstract |
|
| 3:20 PM – 3:45 PM |
Refreshment Break |
|
| 3:45 PM – 4:10 PM |
In Vivo rLenti-Based Gene Transfer for Parkinson’s Disease: Endogenous Dopamine Production by Three-Gene Transfer Using AXO-Lenti-PD
J. Fraser Wright
Chief Technology Officer, Gene Therapies, Axovant Sciences
view bio | view abstract
|
|
| 4:10 PM – 4:55 PM |
Development and Translation of Engineered Tissues with Mechanical and Compositional Properties for Articular Cartilage and Anterior Cruciate Ligament (ACL) Reconstruction
Stephen Kennedy
Executive Vice President and Chief Operating Officer, Histogenics
view bio | view abstract
Lawrence Bonassar
Daljit S. and Elaine Sarkaria Professor, Meinig School of Biomedical Engineering, Sibley School of Mechanical and Aerospace Engineering, Cornell University
view bio | view abstract
Lisa M. Larkin
Chief Executive Officer & Founder, STEL Technologies; Professor, Molecular & Integrative Physiology and Biomedical Engineering, University of Michigan
view bio | view abstract
|
|
| 4:55 PM – 5:20 PM |
Combinatorial Development of Materials for Islet Cell Therapy
Daniel G. Anderson
Associate Professor, Chemical Engineering, Institute for Medical Engineering and Science, Division of Health Science and Technology, and the David H. Koch Institute for Integrative Cancer Research, MIT
view bio | view abstract |
|
| Closing Remarks |
|
| 5:20 PM – 5:30 PM |
Stacy L. Springs
Executive Director, Biomanufacturing Initiatives; Senior Director of Programs, MIT CBI
view bio |
|
| 5:30 PM – 7:00 PM |
Networking Reception and Poster Competition |
|
